Celltrion announced Tuesday the official launch of Omlyclo, its biosimilar treatment for autoimmune diseases, in Brazil. This strategic move marks a significant expansion into the Latin American pharmaceutical market, the region’s largest.
Omlyclo, a biosimilar referencing omalizumab, is approved for the treatment of conditions such as asthma and chronic spontaneous urticaria. This launch positions Celltrion as a key player in Brazil’s growing biosimilar market, responding to the increasing demand for affordable biologic medicines.
Celltrion has already established initial supply routes by winning a state government tender in Santa Catarina, facilitating early distribution through the public healthcare system. The company anticipates securing additional tenders as the Omlyclo rollout progresses.
Concurrently, Celltrion is focusing on the private market, leveraging the existing presence of its other biosimilars, Truxima and Remsima. These products already hold substantial market shares of approximately 40 percent and 60 percent, respectively.
According to Celltrion, recent interactions with healthcare professionals have demonstrated considerable interest in Omlyclo, suggesting positive prospects for wider adoption as prescriptions increase.
“Building on our initial achievements in winning government tenders, we are planning further launches throughout Latin America,” stated Kang Kyung-doo, head of Celltrion’s Latin American division.
jwjeon7625
